STAT
DECEMBER 20, 2022
Lots of people struggle to get enough sleep — and the responsibility for fixing the problem tends to fall on the individual. Experts offer advice like reducing screen time, exercising more, or just going to bed earlier in the evening. But many restless nights can’t be solved with blackout curtains, ear plugs, or other typical suggestions.
PharmaVoice
DECEMBER 22, 2022
Art and science are often viewed as diametric opposites, but these industry insiders say their passion for painting blends into their pharma work.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 19, 2022
A collaboration between academic centres in the UK has won government funding for a digital approach to dysfunctional breathing or dyspnoea, a symptom that affects around 10% of the population. The Engineering and Physical Sciences Research Council (EPSRC) has set aside £400,000 (almost $490,000) for the project, which will help fund work at the Universities of Plymouth, Salford and Stirling, and the Glasgow School of Art.
Pharmaceutical Technology
DECEMBER 21, 2022
Moderna and the UK government have entered a ten-year strategic collaboration to build a messenger ribonucleic acid (mRNA) research, development and manufacturing facility in the country. The latest development comes after the parties announced an agreement in principle in June this year. This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
ID Stewardship
DECEMBER 1, 2022
In this article a pharmacist with advanced training and experience in infectious diseases discusses five things pharmacists should know about ventilator associated pneumonia (VAP). Authored By: Lucia Rose, PharmD, BCIDP. Article Posted 1 December 2022. It was the fall of 2009; I was a proud PGY-1 resident at UMass Medical Center rounding with a large team in the ICU.
European Pharmaceutical Review
DECEMBER 22, 2022
Moderna, Inc. has finalised a strategic partnership with the UK government to establish a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. This milestone follows the agreement in principle between Moderna and the UK Government, announced in June 2022. The Moderna Innovation and Technology Centre (MITC) is intended to provide access to a UK-made supply of COVID-19 jabs.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
PharmaVoice
DECEMBER 1, 2022
Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.
pharmaphorum
DECEMBER 11, 2022
Digital transformation in pharma is not a singular endeavour. It can mean everything from patient-facing disease management apps and wearables to background AI dramatically altering drug discovery or radiological imaging. So, when a life sciences company embarks on a project of digital transformation or innovation, it’s really embarking on multiple projects that span the wide world of pharmaceutical operations.
Pharmaceutical Technology
DECEMBER 23, 2022
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.
PharmExec
DECEMBER 8, 2022
Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
European Pharmaceutical Review
DECEMBER 12, 2022
A thirteen-year-old patient with relapsed T-cell acute lymphoblastic leukaemia (T-ALL) has been the first to be treated with base-edited T-cells via CD7 Chimeric Antigen Receptor (CAR)-T cell therapy, which enabled them to achieve remission 28 days later. . A unique clinical trial for T-ALL. The patient enrolled in the ongoing clinical trial ( NCT05397184 ) went on to receive a second bone marrow transplant after the therapy.
STAT
DECEMBER 13, 2022
An experimental cancer vaccine being developed by the biotechnology firm Moderna and the drug giant Merck reduced the risk that melanoma would return after surgery or that patients would die by 44%, the company said. The data, made public in a press release, represent the first evidence of an effective individualized cancer vaccine based on mRNA, the technology used in the Covid shots.
PharmaVoice
DECEMBER 22, 2022
New Alzheimer's drugs are poised to change the market — and in preclinical arenas, researchers are learning more and more about the disease.
pharmaphorum
DECEMBER 7, 2022
Elon Musk’s brain computer interface (BCI) company Neuralink is being investigated by law enforcement authorities in the US amid allegations of animal welfare violations in its testing facilities. Neuralink’s BCI is intended to treat conditions like blindness and spinal cord injury, as well as provide a way to interact with digital devices using the brain and, according to Musk, is on the brink of moving into the human testing stage.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
Pharmaceutical Technology
DECEMBER 27, 2022
The healthcare industry saw its share of ups and downs in 2022. Our response to the worldwide pandemic evolved over time, and so did the needs of the sector and the people relying on healthcare companies to deliver solutions. Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced.
PhRMA
DECEMBER 15, 2022
Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group (BRG) found that nearly 36% of all Medicare Part B therapy sales occurred at 340B hospitals in 2021 , up nearly 17 percentage points since 2012, meaning care is moving from physician offices and non-340B hospitals to 340B hospitals.
European Pharmaceutical Review
DECEMBER 19, 2022
A new £2.4 million Phase III trial will determine if ketamine-assisted therapy can help those with severe alcohol use disorder to stay off alcohol for longer. Led by the University of Exeter and funded by the Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR), “[t]his is the largest trial of its kind in the world and builds on our earlier, smaller positive trial,” stated Professor Anne Lingford-Hughes, Professor of Addiction Biology at Imperial College
STAT
DECEMBER 12, 2022
This Wednesday will mark two years since nurse Sandra Lindsay became the first person in the U.S. to receive a Covid-19 vaccine outside of a clinical trial. A study released Tuesday by the Commonwealth Fund shows that in those two years, the Covid vaccines have averted over 3 million deaths in the U.S. The Centers for Disease Control and Prevention estimates that more than 1 million Americans have died from Covid-19 since the onset of the pandemic.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PharmaVoice
DECEMBER 16, 2022
A breakdown of how Twitter’s recent shifts are impacting pharma, and how the industry should navigate the platform in 2023.
pharmaphorum
DECEMBER 16, 2022
CSL’s gene therapy for haemophilia B has been recommended for approval by the EMA’s human medicine committee, setting up a decision by the European Commission early next year. The positive opinion for etranacogene dezaparvovec – which was approved as Hemgenix by the FDA last month – raises the prospect of the first one-time therapy in the EU for the bleeding disorder, which affects around 1 in 50,000 of the population, according to the European Haemophilia Network (EUHANET).
Pharmaceutical Technology
DECEMBER 8, 2022
Kite Pharma and Daiichi Sankyo have updated a partnership agreement signed in 2017 for the former’s CAR T-cell therapy, Yescarta (axicabtagene ciloleucel). Under the prior deal, Daiichi Sankyo acquired exclusive rights for the development, manufacturing and commercialisation of Yescarta in Japan. Subsequently, in the same year, Gilead Sciences acquired Kite.
The Thyroid Pharmacist
DECEMBER 28, 2022
As far back as I can remember, I’ve wanted to help people with their health. I grew up watching my mom work as a medical doctor, and always admired her. In elementary school, I was introduced to the scientific method and thought: “This is it! This is what I’m going to do when I grow up!”. I enrolled in a four-year PharmD program (Doctor of Pharmacy) and became a pharmacist with the goal that one day, I would be able to discover new treatments for people who were suffering.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
European Pharmaceutical Review
DECEMBER 22, 2022
The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. mRNA technologies have emerged as an innovative and effective approach to developing new drugs that can potentially transform existing therapies or target difficult‑to‑treat indications including respiratory, cardiac, metabolic and autoimmune diseases, as well as cancer.
STAT
DECEMBER 8, 2022
Doctors across the country, especially those in primary care, have been up in arms about Medicare’s proposed cuts in reimbursement that are scheduled to go into effect on January 1. They are concerned — rightfully so — that these cuts will be ruinous to their practices and compromise the care they can provide to their patients. As an emergency physician, I worry about the cuts for a different reason: emergency departments might soon be filled with more and more people who ca
PharmaVoice
DECEMBER 12, 2022
A recent report ranks the top 20 pharma companies by how well they’re boosting a critical component of health equity.
pharmaphorum
DECEMBER 19, 2022
The US Food and Drug Administration (FDA) has approved Swiss drugmaker Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firedenovec-vncg) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumours. Bladder cancer is one of the more common forms of cancer.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
DECEMBER 18, 2022
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting variation to the marketing authorization (MA) for Moderna ’s Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214) booster for usage in children aged six to 11 years. The 0.25mL dose of the booster vaccine could potentially be used in the European Union (EU) following authorisation in these children a minimum of three months following a previous Covid-19 vaccination.
PharmExec
DECEMBER 14, 2022
Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.
European Pharmaceutical Review
DECEMBER 14, 2022
Moderna, Inc. and Merck have announced that a Phase IIb trial ( NCT03897881 ) of a personalised mRNA cancer vaccine (mRNA-4157/V940), in combination with KEYTRUDA ® , Merck’s anti-PD-1 therapy, demonstrated the first randomised evidence that a personalised neoantigen approach may be beneficial in treating melanoma. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA ® reduced the risk of recurrence or death by 44 percent (HR=0.56 [95 percent CI, 0.31-1.08]; one-sided p-valu
STAT
DECEMBER 2, 2022
SAN FRANCISCO — Scientific meetings about Alzheimer’s disease can be funereal affairs, with researchers from around the world gathering in hopes that the latest in a long line of negative clinical trials might light the path to a long-awaited success. This year was different. Nearly 2,000 people showed up to the Clinical Trials in Alzheimer’s Disease meeting, a conference record, to hear about lecanemab, a drug from Eisai and Biogen that appears to have broken the decades-lo
PharmaVoice
DECEMBER 19, 2022
A series of small successes showed promise for the future of blood cancer treatments, particularly in the arena of drug combinations.
Expert insights. Personalized for you.
364 
Let's personalize your content